BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu Sells 6,725 Shares

BeiGene, Ltd. (NASDAQ:BGNEGet Rating) COO Xiaobin Wu sold 6,725 shares of the stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $164.35, for a total transaction of $1,105,253.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

BGNE opened at $147.29 on Friday. The firm has a market cap of $15.12 billion, a P/E ratio of -7.33 and a beta of 0.85. The business’s fifty day simple moving average is $182.06 and its 200 day simple moving average is $250.09. BeiGene, Ltd. has a 52 week low of $136.09 and a 52 week high of $426.56. The company has a quick ratio of 4.61, a current ratio of 4.76 and a debt-to-equity ratio of 0.03.

BeiGene (NASDAQ:BGNEGet Rating) last released its earnings results on Thursday, May 5th. The company reported ($4.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.12) by ($0.12). The firm had revenue of $306.60 million during the quarter, compared to analysts’ expectations of $300.41 million. BeiGene had a negative net margin of 120.15% and a negative return on equity of 32.85%. The business’s revenue for the quarter was down 49.4% on a year-over-year basis. As a group, equities analysts expect that BeiGene, Ltd. will post -15.66 EPS for the current fiscal year.

A number of research firms have weighed in on BGNE. Deutsche Bank Aktiengesellschaft began coverage on BeiGene in a research report on Monday, February 7th. They set a “buy” rating for the company. Zacks Investment Research upgraded shares of BeiGene from a “sell” rating to a “buy” rating and set a $179.00 price objective for the company in a research report on Monday, May 2nd. SVB Leerink downgraded BeiGene from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $300.00 to $177.00 in a research note on Thursday, March 17th. Morgan Stanley boosted their target price on BeiGene from $330.00 to $338.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Finally, StockNews.com began coverage on shares of BeiGene in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $281.25.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace North America L.P. acquired a new position in shares of BeiGene during the 1st quarter valued at about $76,000. Amundi Pioneer Asset Management Inc. boosted its holdings in shares of BeiGene by 9.7% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 17,001 shares of the company’s stock valued at $2,244,000 after purchasing an additional 1,500 shares during the last quarter. Morgan Stanley boosted its holdings in shares of BeiGene by 205.8% in the 2nd quarter. Morgan Stanley now owns 114,502 shares of the company’s stock valued at $39,296,000 after purchasing an additional 77,060 shares during the last quarter. Raymond James & Associates raised its position in shares of BeiGene by 11.8% in the 3rd quarter. Raymond James & Associates now owns 11,922 shares of the company’s stock worth $4,328,000 after buying an additional 1,259 shares during the period. Finally, Deutsche Bank AG boosted its holdings in BeiGene by 34.5% in the third quarter. Deutsche Bank AG now owns 110,440 shares of the company’s stock valued at $40,088,000 after acquiring an additional 28,346 shares during the last quarter.

About BeiGene (Get Rating)

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

See Also

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.